Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Moderna Vaccine Launch Strategy Eyes 3 Pipeline Assets & Oncology Milestones
Moderna shares climb 6% as the firm targets the launch of flu-COVID, seasonal flu, and norovirus vaccines, alongside key oncology data readouts.
Sevuparin Modulates Chronic Kidney Disease Anemia Biomarkers at EHA2026
Modus Therapeutics reports positive preclinical data on sevuparin for chronic kidney disease (CKD) anemia, highlighting synergistic effects with EPO.
Alzheimer's Disease Treatment Options: Copper Drug Restores Memory Loss
A Monash University study shows that copper compound Cu(ATSM) repairs the blood-brain barrier waste-removal system and lowers toxic amyloid-beta by 42%.
Pancreatic Cancer Research Breakthrough: Caspase-8 Triggers Tumor Death
Researchers at the University of Cologne discover a key vulnerability in KRAS-mutant pancreatic cancer cells that primes them for necroptotic cell death.
Alzheimer's Clinical Trials: First Patient Dosed with Leronlimab
CytoDyn and Weill Cornell Medicine initiate a Phase 2a clinical study, dosing the first Alzheimer's disease patient with humanized monoclonal antibody leronlimab.
FDA Expands Approval of Sanofi's Tzield for Type 1 Diabetes in Kids
Sanofi's Tzield receives an expanded FDA drug approval for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes.
Prader-Willi Syndrome Treatment: Setmelanotide Phase 2 Results
Rhythm Pharmaceuticals reports a significant 7-point hyperphagia reduction in its Phase 2 trial of setmelanotide for Prader-Willi syndrome.
FDA Grants Fast Track Designation for Novel Sepsis Treatment Isupartob
Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium, accelerating the clinical trials and development of a novel sepsis treatment.
Symeres Expands Spray Drying Capabilities for Complex Drug Formulation
Symeres enhances its CMC site in New Jersey with expanded spray drying capabilities, optimizing drug formulation development for poorly soluble candidates.
Alteogen Unveils Breakthrough Preclinical Results for Subcutaneous ADCs
Alteogen reveals preclinical data for an antibody-drug conjugate (ADC) subcutaneous formulation using ALT-B4, showing improved absorption and safety profiles.
JW Pharma Restores Cognitive Function with Rare Disease Drug Candidate
JW Pharmaceutical shares preclinical results for DDC-02 at the World Orphan Drug Congress, showing restored cognitive function in rare neurodevelopmental disorders.
Purple Biotech Unveils IM1240 Cancer Treatment Preclinical Data at EACR
Purple Biotech presents promising preclinical data at EACR 2026 for IM1240, a novel cancer treatment showing anti-tumor activity in hard-to-treat solid tumors.
1
2
3
4
5
6
7
8
